Clinical trial
A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's 10-Valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) Administered in a 2+1 Schedule to Healthy Infants in The Gambia
NCT03896477 is registered in ClinicalTrials.gov with PATH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's 10-Valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) Administered in a 2+1 Schedule to Healthy Infants in The Gambia
- Lead sponsor
- PATH
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 18, 2019
- Completion date
- December 17, 2020
- Enrollment
- 660 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.